Immunologic adjuvant

Dr. Philip Krause to Provide Strategic Advice to Adjuvance

Retrieved on: 
Tuesday, January 25, 2022
Oncology, Professional Services, Health, Infectious Diseases, Venture Capital, Pharmaceutical, Biotechnology, Center for Biologics Evaluation and Research, Vaccine, Center, TLR, National, Shingles, Research, MPL, US Foods, Vaccination, FDA, Pain, Virology, Twitter, QS21, Vaccine Research Center, Food, MAK Technologies, Inc., LinkedIn, Global health, Infection, NIH, Face, Torso, Review, MD, Disease, Pharmaceutical industry, Immunologic adjuvant, TQL-1055, Shingles, Adjuvance Technologies, TQL-1055, SHINGLES, ADJUVANCE TECHNOLOGIES

He will provide strategic consulting on vaccine development, US and international regulatory affairs, clinical trial design and evaluation, virology and immunology and global health.

Key Points: 
  • He will provide strategic consulting on vaccine development, US and international regulatory affairs, clinical trial design and evaluation, virology and immunology and global health.
  • Dr. Krause said, I look forward to this opportunity to provide advice and counsel to the Adjuvance leadership team on the development of their innovative saponin adjuvant platform, and their lead vaccine candidates.
  • Adjuvance is designing new combination adjuvants, with TQL-1055 as the foundation, to produce different types of immune responses.
  • About Adjuvance Technologies: Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to making vaccines better through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing.

Adjuvance Technologies Announces Issuance of U.S. Patent Covering Semi-Synthetic Saponin Adjuvants

Retrieved on: 
Friday, January 7, 2022
Professional Services, Health, Infectious Diseases, Venture Capital, Pharmaceutical, Biotechnology, Face, Shingles, Toxicity, Vaccine, Disclosure, MSK, Memorial Sloan Kettering Cancer Center, Perfect Web Technologies, Inc. v. InfoUSA, Inc., United States patent law, Torso, USPTO, National, Twitter, Disease, LinkedIn, Immunization, Infection, Patent, Method, Pain, Technology, QS-21, TLR, Vaccination, United States Patent and Trademark Office, NIH, MPL, Immunologic adjuvant, TQL-1055, Shingles, Adjuvance Technologies, TQL-1055, SHINGLES, ADJUVANCE TECHNOLOGIES

Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.

Key Points: 
  • Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
  • The patent includes 21 claims and follows issuance of similar patents in certain other countries around the world.
  • The patent has been assigned to Adjuvance and Memorial Sloan Kettering Cancer Center (New York, USA), where advanced synthetic saponin technology was first developed.
  • About Adjuvance Technologies: Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to making vaccines better through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing.

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Adjuvants, Health sciences, Health, Clinical trials, Economy of New York City, NASDAQ, Immunologic adjuvant, Vaccine

The stock options were granted on August 2, 2021 at an exercise price of $9.45 per share, which is equal to the closing price of Dynavax common stock on the date of grant.

Key Points: 
  • The stock options were granted on August 2, 2021 at an exercise price of $9.45 per share, which is equal to the closing price of Dynavax common stock on the date of grant.
  • The options were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of a stock option agreement covering the grant and Dynavax' 2021 Inducement Award Plan, which was adopted January 9, 2021 and provides for the granting of stock options to new employees.
  • Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines.
  • Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.

Global Vaccine Adjuvants Market Opportunity Outlook to 2027: The Strategies Adopted by Key Players - ResearchAndMarkets.com

Retrieved on: 
Friday, July 23, 2021
Health, Pharmaceutical, Medical specialties, Immunology, Health care, Medicine, Adjuvants, Immunologic adjuvant, Vaccine, Clinical trials, Polyclonal antibodies

High toxicity of adjuvants on application, huge investment required for developing a new adjuvant and strict regulatory requirements are some restraining factors which are expected to hamper the global vaccine adjuvants market growth.

Key Points: 
  • High toxicity of adjuvants on application, huge investment required for developing a new adjuvant and strict regulatory requirements are some restraining factors which are expected to hamper the global vaccine adjuvants market growth.
  • On the basis of type, the global vaccine adjuvants market is segmented into a Pathogen, Adjuvant Emulsion, Combination, Particulate, and Others.
  • The particulate type is expected to hold the largest market share in vaccine adjuvants market.
  • All these factors are expected to contribute the global vaccine adjuvants market growth over the forecast period.

Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate

Retrieved on: 
Tuesday, July 6, 2021
Vaccines, Medical specialties, Medicine, COVID-19 vaccines, Clinical trials, COVID-19 vaccine, Vaccine, Immunologic adjuvant, Hepatitis B vaccine, VLA2001

"We are pleased to collaborate with Dynavax, and our collaboration will produce yet another vital vaccine against the spread of COVID-19.

Key Points: 
  • "We are pleased to collaborate with Dynavax, and our collaboration will produce yet another vital vaccine against the spread of COVID-19.
  • Dynavax developed CpG 1018 adjuvant to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
  • CpG 1018 adjuvant provides a well-developed technology and a significant safety database, potentially accelerating the development and large-scale manufacturing of a COVID-19 vaccine.
  • Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, July 2, 2021
Medical specialties, Adjuvants, Health sciences, Health, COVID-19 vaccines, Clinical trials, Immunologic adjuvant, Immunology, Vaccine, VLA2001

The stock options were granted on July 1, 2021 at an exercise price of $10.23 per share, which is equal to the closing price of Dynavax common stock on the date of grant.

Key Points: 
  • The stock options were granted on July 1, 2021 at an exercise price of $10.23 per share, which is equal to the closing price of Dynavax common stock on the date of grant.
  • The options were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of a stock option agreement covering the grant and Dynavax' 2021 Inducement Award Plan, which was adopted January 9, 2021 and provides for the granting of stock options to new employees.
  • Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines.
  • Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.

Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate

Retrieved on: 
Wednesday, June 30, 2021
Vaccines, Medical specialties, Medicine, Clinical trials, COVID-19 vaccines, Adjuvants, SCB-2019, Science and technology in China, Immunology, COVID-19 vaccine, Immunologic adjuvant, Hepatitis B vaccine

Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.

Key Points: 
  • Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.
  • Clover's COVID-19 vaccine candidate is the combination of SCB-2019 and two adjuvants, Dynavax's CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
  • Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
  • Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.

Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate

Retrieved on: 
Wednesday, June 30, 2021
Vaccines, Medical specialties, Medicine, Clinical trials, COVID-19 vaccines, Adjuvants, SCB-2019, Science and technology in China, Immunology, COVID-19 vaccine, Immunologic adjuvant, Hepatitis B vaccine

Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.

Key Points: 
  • Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.
  • Clover's COVID-19 vaccine candidate is the combination of SCB-2019 and two adjuvants, Dynavax's CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
  • Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
  • Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.

Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, June 29, 2021
Adjuvants, Health sciences, Health, Medical specialties, Immunologic adjuvant, Strike price, Option, VLA2001

The stock option was granted with an exercise price of $9.29 per share, which is equal to the closing price of Dynavax common stock on the date of grant, and was provided as a material inducement to Mr. Slebir's employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock option was granted with an exercise price of $9.29 per share, which is equal to the closing price of Dynavax common stock on the date of grant, and was provided as a material inducement to Mr. Slebir's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The option is subject to the terms and conditions of a stock option agreement covering the grant and Dynavax's 2021 Inducement Award Plan, which was adopted on January 9, 2021 and provides for the granting of stock options to new employees.
  • Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines.
  • Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.

NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Thursday, May 20, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Immunology, Antigen, Biomolecules, Immune system, Immunologic adjuvant, Health care, Medicine, Health, NT-I7, NeoImmuneTech, NT-I7, NEOIMMUNETECH

b'NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that new data from two clinical trials evaluating the company\xe2\x80\x99s lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in a virtual platform June 4-8, 2021.

Key Points: 
  • b'NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that new data from two clinical trials evaluating the company\xe2\x80\x99s lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in a virtual platform June 4-8, 2021.
  • IL-7 is a fundamental cytokine for na\xc3\xafve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases).
  • In clinical trials to date, NT-I7 has exhibited favorable PK/PD and safety profiles, both as a monotherapy and in combination with other anticancer treatments.
  • NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant.